Healthcare
Temasek acquires 18% stake in Indian hospital operator
Temasek Holdings - an investment arm of the Singapore government - has acquired a 17.74% stake in Global Health, which operates the Mendanta super specialty hospital in Gurgaon, India.
Australian medical research fund backs antibody start-up
Solvanix, an Australian early-stage biotech company that has developed a technology for improving drug stability, has received A$2 million ($1.6 million) in seed funding from the Medical Research Commercialization Fund (MRCF).
CDC commits $48m to India healthcare provider
UK development finance institution (DFI) CDC Group has invested $48 million in Indian multi-specialty healthcare provider Narayana Hrudayalaya Hospitals (NH) in return for a small minority stake.
Yunfeng joins $1.6b deal for China drug maker Baiyunshan
Yunfeng Capital and other investors have agreed to invest up to RMB10 billion ($1.6 billion) in Chinese drug maker Guangzhou Baiyushan Pharmaceutical Holdings.
China's BVCF provides $8m round for US biotech firm
China-focused biotech investor BVCF has led an $8 million Series A round of funding for DiaCarta, a US-based firm that develops test kits for detecting cancer.
Ally Bridge leads $25m round for Shanghai Hua Medicine
Ally Bridge Group, a healthcare-focused PE firm, has led a $25 million Series B round of funding for Hua Medicine, a Shanghai-based clinical-stage biotech company.
MSPEA enters the China hospital space
To Homer Sun, CIO at Morgan Stanley Private Equity Asia (MSPEA), the current climate in China’s hospital services space is reminiscent of pharmaceuticals circa 2008. Government policy was pushing the industry towards consolidation and MSPEA capitalized,...
Australian cancer drug developer raises $10m Series B round
Australian biopharmaceutical start-up EnGeneIC has received $10 million in a Series B round of funding led by Boston-based healthcare specialist GRT Capital Partners.
MSPEA, Sihuan Pharma invest in Chinese hospitals - UPDATE
Morgan Stanley Private Equity Asia (MSPEA) has teamed up with Sihuan Pharmaceuticals – one of its portfolio companies – and that company’s chairman to invest RMB1.24 billion ($200 million) in two Chinese hospitals.
Hony, Goldman lead investment in Neusoft medical device units
A consortium including Hony Capital, Goldman Sachs and Canada Pension Plan Investment Board (CPPIB) has agreed to invest $610 million in two medical device subsidiaries owned by Neusoft Corporation, a Chinese IT services provider.
Fidelity backs China-based antibody specialist
Two Fidelity funds have participated in a Series A round of funding worth $8 million for Adagene, a China-based life sciences company that specializes in smart antibody technology.
Japan PE acquires plastics manufacturer, elderly care business
Mid-market GP Japan Private Equity has acquired plastics manufacturer Sekisui Chemicals and care home services business Healthy Service via its third buyout fund.
Qiming leads $10m round for China biopharma player
Qiming Venture Partners has led a $10 million Series A round of funding for CANbridge Life Science, a Beijing-based biopharmaceutical firm.
China healthcare: Technology transfer
Healthcare-focused private equity firms want to take technologies from developed markets into China, leveraging rising domestic demand. It is a lucrative strategy, but not necessarily a straightforward one
Portfolio: Advent International and CARE Hospitals
A majority stake in CARE Hospitals has allowed Advent International into India’s fast-growing healthcare sector. Rather than blindly pursuing expansion, the PE firm is building a business tailored to local demand
AIA, Nest set up accelerator for Hong Kong start-ups
AIA Group has teamed up with early-stage investor Nest to form a Hong Kong-based accelerator that will support start-ups with technologies relevant to the insurance and healthcare industries.
JD Capital buys traditional Chinese medicine business
JD Capital has bought a 60% stake in Baoding Zhong Yao, a traditional Chinese medicine (TCM) manufacturer.
BVCF leads Series A for Shanghai immunotherapy firm
China-focused healthcare investor BVCF has led an undisclosed Series A round of funding for CARsgen, an immunotherapy firm that focuses on treating cancer.
China's Ally Bridge ventures into German healthcare
Ally Bridge Group, a healthcare-focused PE firm based in Hong Kong and the US, has made its first investment in Europe, participating in a EUR6.6 million ($8 million) round of funding for Pieris, a Munich-based clinical-stage biotechnology firm.
Lighthouse leads $5m Series C round for hearing aid maker
Shanghai-based Lighthouse Capital has led a $5 million Series C round of funding for affordable hearing aid maker iHear Medical.
Fosun, Nanjing Sinolife to acquire New Zealand nutrients maker
Fosun Capital and Nanjing Sinolife United have formed a joint venture to acquire Good Health Products, a New Zealand-based nutritional supplements maker and distributor, for NZ$23.37 million ($18 million).
Fidelity commits $10m to China medical device maker Eyebright
Fidelity Growth Partners Asia and Fidelity Biosciences have committed RMB62.5 million ($10 million) to Eyebright Medical Technology, a Chinese ophthalmic medical devices manufacturer.
J-Star in hospice care double deal
Not for the first time, J-Star planted the seeds of its latest investment while in pursuit of another deal.
Taiwan's Fubon commits $30m to US-based Athyrium credit fund
Fubon Life, the second-largest insurer in Taiwan, has committed $30 million to Athyrium Capital Management’s healthcare-focused credit fund.